Axsome Therapeutics Stock Technical Analysis
| AXSM Stock | USD 185.27 0.10 0.05% |
As of the 29th of January, Axsome Therapeutics shows the Downside Deviation of 1.6, mean deviation of 1.91, and Risk Adjusted Performance of 0.1435. Axsome Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Axsome Therapeutics standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Axsome Therapeutics is priced correctly, providing market reflects its regular price of 185.27 per share. Given that Axsome Therapeutics has jensen alpha of 0.6371, we suggest you to validate Axsome Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.
Axsome Therapeutics Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Axsome, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to AxsomeAxsome Therapeutics' Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.Axsome Therapeutics Analyst Consensus
| Target Price | Advice | # of Analysts | |
| 210.19 | Strong Buy | 19 | Odds |
Most Axsome analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Axsome stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Axsome Therapeutics, talking to its executives and customers, or listening to Axsome conference calls.
Will Pharmaceuticals sector continue expanding? Could Axsome diversify its offerings? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Axsome Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.66) | Revenue Per Share | Quarterly Revenue Growth 0.632 | Return On Assets | Return On Equity |
Investors evaluate Axsome Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Axsome Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Axsome Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Axsome Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Axsome Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Axsome Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Axsome Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Axsome Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Axsome Therapeutics.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Axsome Therapeutics on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Axsome Therapeutics or generate 0.0% return on investment in Axsome Therapeutics over 90 days. Axsome Therapeutics is related to or competes with Nuvalent, Abivax SA, Cytokinetics, Rhythm Pharmaceuticals, Arrowhead Pharmaceuticals, Crispr Therapeutics, and Vaxcyte. Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervou... More
Axsome Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Axsome Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Axsome Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.6 | |||
| Information Ratio | 0.1623 | |||
| Maximum Drawdown | 26.78 | |||
| Value At Risk | (2.36) | |||
| Potential Upside | 4.2 |
Axsome Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Axsome Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Axsome Therapeutics' standard deviation. In reality, there are many statistical measures that can use Axsome Therapeutics historical prices to predict the future Axsome Therapeutics' volatility.| Risk Adjusted Performance | 0.1435 | |||
| Jensen Alpha | 0.6371 | |||
| Total Risk Alpha | 0.3153 | |||
| Sortino Ratio | 0.3423 | |||
| Treynor Ratio | (1.70) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Axsome Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Axsome Therapeutics January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1435 | |||
| Market Risk Adjusted Performance | (1.69) | |||
| Mean Deviation | 1.91 | |||
| Semi Deviation | 1.2 | |||
| Downside Deviation | 1.6 | |||
| Coefficient Of Variation | 542.13 | |||
| Standard Deviation | 3.38 | |||
| Variance | 11.43 | |||
| Information Ratio | 0.1623 | |||
| Jensen Alpha | 0.6371 | |||
| Total Risk Alpha | 0.3153 | |||
| Sortino Ratio | 0.3423 | |||
| Treynor Ratio | (1.70) | |||
| Maximum Drawdown | 26.78 | |||
| Value At Risk | (2.36) | |||
| Potential Upside | 4.2 | |||
| Downside Variance | 2.57 | |||
| Semi Variance | 1.45 | |||
| Expected Short fall | (2.54) | |||
| Skewness | 4.4 | |||
| Kurtosis | 28.18 |
Axsome Therapeutics Backtested Returns
Axsome Therapeutics appears to be very steady, given 3 months investment horizon. Axsome Therapeutics secures Sharpe Ratio (or Efficiency) of 0.16, which signifies that the company had a 0.16 % return per unit of risk over the last 3 months. By analyzing Axsome Therapeutics' technical indicators, you can evaluate if the expected return of 0.57% is justified by implied risk. Please makes use of Axsome Therapeutics' Risk Adjusted Performance of 0.1435, downside deviation of 1.6, and Mean Deviation of 1.91 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Axsome Therapeutics holds a performance score of 13. The firm shows a Beta (market volatility) of -0.36, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Axsome Therapeutics are expected to decrease at a much lower rate. During the bear market, Axsome Therapeutics is likely to outperform the market. Please check Axsome Therapeutics' expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Axsome Therapeutics' price patterns will revert.
Auto-correlation | 0.84 |
Very good predictability
Axsome Therapeutics has very good predictability. Overlapping area represents the amount of predictability between Axsome Therapeutics time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Axsome Therapeutics price movement. The serial correlation of 0.84 indicates that around 84.0% of current Axsome Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.84 | |
| Spearman Rank Test | 0.65 | |
| Residual Average | 0.0 | |
| Price Variance | 220.1 |
Axsome Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Axsome Therapeutics Technical Analysis
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Normalized Average True Range is used to analyze tradable apportunities for Axsome Therapeutics across different markets.
About Axsome Therapeutics Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Axsome Therapeutics on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Axsome Therapeutics based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Axsome Therapeutics price pattern first instead of the macroeconomic environment surrounding Axsome Therapeutics. By analyzing Axsome Therapeutics's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Axsome Therapeutics's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Axsome Therapeutics specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2023 | 2024 | 2025 | 2026 (projected) | Payables Turnover | 0.64 | 0.46 | 0.42 | 0.44 | Days Of Inventory On Hand | 211.94 | 172.42 | 198.29 | 252.16 |
Axsome Therapeutics January 29, 2026 Technical Indicators
Most technical analysis of Axsome help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Axsome from various momentum indicators to cycle indicators. When you analyze Axsome charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1435 | |||
| Market Risk Adjusted Performance | (1.69) | |||
| Mean Deviation | 1.91 | |||
| Semi Deviation | 1.2 | |||
| Downside Deviation | 1.6 | |||
| Coefficient Of Variation | 542.13 | |||
| Standard Deviation | 3.38 | |||
| Variance | 11.43 | |||
| Information Ratio | 0.1623 | |||
| Jensen Alpha | 0.6371 | |||
| Total Risk Alpha | 0.3153 | |||
| Sortino Ratio | 0.3423 | |||
| Treynor Ratio | (1.70) | |||
| Maximum Drawdown | 26.78 | |||
| Value At Risk | (2.36) | |||
| Potential Upside | 4.2 | |||
| Downside Variance | 2.57 | |||
| Semi Variance | 1.45 | |||
| Expected Short fall | (2.54) | |||
| Skewness | 4.4 | |||
| Kurtosis | 28.18 |
Axsome Therapeutics January 29, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Axsome stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 15,514 | ||
| Daily Balance Of Power | 0.02 | ||
| Rate Of Daily Change | 1.00 | ||
| Day Median Price | 184.12 | ||
| Day Typical Price | 184.50 | ||
| Price Action Indicator | 1.21 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Will Pharmaceuticals sector continue expanding? Could Axsome diversify its offerings? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Axsome Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.66) | Revenue Per Share | Quarterly Revenue Growth 0.632 | Return On Assets | Return On Equity |
Investors evaluate Axsome Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Axsome Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Axsome Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Axsome Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Axsome Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Axsome Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.